A clinical study to evaluate the efficacy of asafoetida in the management of irritable bowel syndrome

Abstract

Irritable bowel syndrome (IBS) is not life-threatening, but it has enormous influence on quality of life (QOL) and mental health. Its chronic nature, signs, and symptoms, which vary periodically from mild to severe, have many negative effects on the quality of life for the sufferer; therefore, the appropriate treatment of these patients is highly important and can improve patients' Quality of life. This clinical study is aimed at evaluating the therapeutic efficacy of Asafoetida in improving the quality of life of IBS patients through the IBS-QOL questionnaire. This study was done on 20 patients, where 10 patients were given Asafoetida and 10 patients were given a placebo. The statistical results showed that Asafoetida gave better results compared to the control group.